Fundraising Fox

Sirnaomics

Gaithersburg, US · Delaware corporation

sirnaomics.com ↗

Sirnaomics is an RNA therapeutics company developing RNA interference (RNAi) drugs using its proprietary PNP (Peptide Nanoparticle) delivery platform for extra-hepatic delivery and its GalAHead technology for controlling therapeutic duration. Its pipeline spans oncology, regenerative and aesthetic medicine, and cardiovascular and metabolic diseases.

BiotechHealthtech

Founders & leadership

Y(
Yang (Patrick) Lu, PhDFounder
GJ
George JiExecutive
MM
Michael MolyneauxExecutive

Board

XD
Xiaochang DaiBoard director
PL
Ping LauBoard director
MG
Mike GhiasBoard director

Reported raises · per SEC filings

Form D private placements

$162M disclosed across 5 rounds · 2016–2020

▶$15MraisedDec 2020 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael V Molyneaux, MD, MBAExecutive Officer, Director
  • Mike M Ghias, MBADirector
  • Yang (Patrick) Lu, PhDExecutive Officer, Director
  • Rong Lu, MBADirector
  • Da LiuDirector
  • Xiaochang Dai, PhDDirector
  • Huang Mingcong (Cooper)Director
Offering amount
$15M
Amount sold
$15M
Minimum investment
$1M
First sale
Oct 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$89MraisedDec 2020 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rong Lu, MBADirector
  • Mongcong (Cooper) HuangDirector
  • Xiaochang Dai, PhDDirector
  • Michael V Molyneaux, MD, MBAExecutive Officer, Director
  • Mike M Ghias, MBADirector
  • Yang (Patrick) Lu, PhDExecutive Officer, Director
  • Da LiuDirector
Offering amount
$89M
Amount sold
$89M
Minimum investment
$1M
First sale
Oct 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$23MraisedJul 2019 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick Y Lu, PhDExecutive Officer, Director
  • Mike Ghias, MBADirector
  • Rong Lu, MBADirector
  • Xiaochang Dai, PhDDirector
  • Ping Lau, MBADirector
  • Michael Molyneaux, MD, MBAExecutive Officer, Director
Offering amount
$23M
Amount sold
$23M
Minimum investment
$1M
First sale
Mar 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedJul 2019 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick Y Lu, PhDExecutive Officer, Director
  • Mike Ghias, MBADirector
  • Xiaochang Dai, PhDDirector
  • Ping Lau, MBADirector
  • Rong Lu, MBADirector
  • Michael Molyneaux, MD, MBAExecutive Officer, Director
Offering amount
$25M
Amount sold
$25M
Minimum investment
$118K
Finders' fees
$100K
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedApr 2016 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Xiaochang DaiDirector
  • Yang (Patrick) Lu, PhDExecutive Officer, Director
  • Ping LauDirector
  • George JiExecutive Officer
  • Michael MolyneauxExecutive Officer, Director
  • Mike GhiasDirector
Offering amount
$10M
Amount sold
$10M
Minimum investment
$2.5M
First sale
Apr 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 8

by search overlap
Sionnatx43 shared keywordsSionna Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule medicines for cystic fibrosis by stabilizing the CFTR protein's NBD1 domain to correct defects from the F508del mutation. It is also building a portfolio of complementary CFTR modulators intended to work with its NBD1 stabilizers to restore CFTR function in CF patients.
Ronatherapeutics38 shared keywordsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
Switch Therapeutics30 shared keywordsSwitch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
Syrna Therapeutics28 shared keywordsSyrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.
Siriusrna24 shared keywordsSirius is a biotech company developing RNAi-based therapies focused on cardiovascular diseases for global markets. It applies RNA interference technology to create new treatment options for patients.
Day One Biopharmaceuticals23 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Orna23 shared keywordsOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Inspirna21 shared keywordsInspirna is a clinical-stage biopharmaceutical company developing first-in-class cancer therapeutics, including oral small molecules and biologics that target newly discovered drivers of metastasis in common cancers such as colorectal, non-small cell lung, and endometrial cancer. It uses its proprietary RNA-DRIVEr platform and microRNA mapping to identify cancer drivers for patients with high unmet medical needs.

Companies competing with Sirnaomics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Sirnaomics do?
Sirnaomics is an RNA therapeutics company developing RNA interference (RNAi) drugs using its proprietary PNP (Peptide Nanoparticle) delivery platform for extra-hepatic delivery and its GalAHead technology for controlling therapeutic duration. Its pipeline spans oncology, regenerative and aesthetic medicine, and cardiovascular and metabolic diseases.
Who founded Sirnaomics?
Sirnaomics was founded by Yang (Patrick) Lu, PhD.
How much funding has Sirnaomics raised?
Sirnaomics has disclosed $162M raised across 5 rounds.
Where is Sirnaomics headquartered?
Sirnaomics is headquartered in Gaithersburg, US.